Abstract 681
Background
Red blood cell distribution width (RDW) is a parameter measured in blood sample tests that reflects the variation in the volume of erythrocytes and used to differentiate an anemic state. The RDW has been used to predict a poor survival in various types of cancer; however, the prognostic impact of the RDW in resected pathological stage I non-small cell lung cancer (NSCLC) patients remains to be elucidated.
Methods
A total of 273 patients with resected pathological stage I NSCLC were included in this study. The cut-off value of RDW was set at 14.5, which was the upper limit of the normal range of the RDW. The controlling nutritional status (CONUT) score, which was calculated by the albumin, cholesterol and the lymphocyte count, was also investigated.
Results
Among 273 patients, 34 (12.5%) were RDW-high, while 239 (87.5%) were RDW-low. RDW-high was significantly associated with a lower body mass index (P < 0.01), a lower level of hemoglobin (P < 0.01), a higher level of C-reactive protein (P < 0.01), and a high CONUT score (P = 0.03) than RDW-low. Patients with RDW-high exhibited significantly shorter recurrence-free and overall survivals (RFS and OS, respectively) than those with RDW-low (P < 0.01 and P < 0.01, respectively). Multivariate analyses showed that the RDW was an independent prognostic factor for both the RFS and OS (RFS, hazard ratio [HR]: 2.16, 95% confidence interval [CI]: 1.14-3.95, P = 0.02; OS, HR: 2.44, 95% CI: 1.28-4.49, P < 0.01).
Conclusions
The RDW was shown to be a potent prognosticator for the RFS and OS in resected pathological stage I NSCLC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3157 - Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)
Presenter: Yihebali Chi
Session: Poster Display session 1
Resources:
Abstract
3710 - The effect of treatment line on the efficacy of Anlotinib hydrochloride in advanced alveolar soft part sarcoma patients
Presenter: Zhiwei Fang
Session: Poster Display session 1
Resources:
Abstract
3184 - Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
798 - Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumor (TGCT): characterization of hepatic adverse reactions (ARs)
Presenter: Sebastian Bauer
Session: Poster Display session 1
Resources:
Abstract
6117 - VEGFR2 and ITGA polymorphisms as novel pan-sarcoma biomarkers for sensitivity prediction as well as toxicity prevention anti-angiogenesis therapy in pediatric and young adult
Presenter: Qiyuan Bao
Session: Poster Display session 1
Resources:
Abstract
5450 - Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa.
Presenter: Roberta Sanfilippo
Session: Poster Display session 1
Resources:
Abstract
4279 - Efficacy and Safety of VEGFR2 Inhibitor Apatinib combined with chemotherapy for Sarcoma in Stage IV
Presenter: Zhiwu Ren
Session: Poster Display session 1
Resources:
Abstract
5929 - Outcomes of metastatic soft tissue sarcoma treated with Pazopanib from dedicated medical oncology sarcoma clinic: A holistic care approach from a developing country
Presenter: Akhil Kapoor
Session: Poster Display session 1
Resources:
Abstract
2469 - Inhibition of mTOR signaling enhances Trabectedin activity in Soft Tissue Sarcoma
Presenter: David Moura
Session: Poster Display session 1
Resources:
Abstract
4210 - Efficacy and safety of apatinib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial
Presenter: Zhaolun Cai
Session: Poster Display session 1
Resources:
Abstract